News Release

 

Back
 

Four AmerisourceBergen Directors Re-Elected at Annual Meeting of Stockholders

03/04/05

PHILADELPHIA--(BUSINESS WIRE)--March 4, 2005--At the AmerisourceBergen Corporation (NYSE:ABC) annual meeting of stockholders, held today in Philadelphia, Company stockholders re-elected four directors: Rodney H. Brady, Charles H. Cotros, Jane E. Henney, MD, and R. David Yost. In addition, stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2005 fiscal year.

During the meeting stockholders also heard a review of the Company's activities and outlook from Chief Executive Officer R. David Yost.

Mr. Brady, 71, has been a member of the Board of Directors since AmerisourceBergen's inception almost four years ago, having previously served on the Bergen Brunswig Board of Directors since 1973. Since 1996, he has served as President and Chief Executive Officer of Deseret Management Corporation. Previously, he was President and Chief Executive Officer of Bonneville International Corporation from 1985 to 1996, and was President of Weber State University from 1978 to 1985. He also served as Assistant Secretary of the U.S. Department of Health, Education and Welfare in the early 1970s.

Mr. Cotros, 67, has been a member of the Board of Directors since 2002. He became Chairman and Chief Executive Officer of Allied Waste Industries, Inc. in October of last year and has been a Director of Allied since July 2004. Previously, he served as Chairman and Chief Executive Officer of Sysco Corporation from 2000 to 2002, and held a variety of positions at Sysco, including Chief Operating Officer and President.

Dr. Henney, 57, has been an AmerisourceBergen Director since 2002 and also serves as a Director of AstraZeneca PLC and Cigna Corporation. She has been Senior Vice President and Provost for Health Affairs at the University of Cincinnati since 2003, and previously was Senior Scholar in Residence at the Association of Academic Health Centers in Washington, D.C. from 2001 to 2003. From 1998 to 2001, she was Commissioner of Food and Drugs at the U.S. Food and Drug Administration, where she served as Deputy Commissioner of Operations from 1992 to 1994. From 1994 to 1998, Dr. Henney, who is a medical oncologist, was Vice President of Health Sciences at the University of New Mexico. In the early 1980s, she also held several posts at the National Cancer Institute, including Deputy Director.

Mr. Yost, 57, has been a member of the Board of Directors and the Company's Chief Executive Officer since AmerisourceBergen's inception. Previously, he was Chairman and Chief Executive Officer and a Director of AmeriSource Health Corporation. He also held a variety of other positions at AmeriSource and its predecessor companies after joining the company in 1974, including President and Executive Vice President--Operations.

The AmerisourceBergen Board of Directors is composed of ten directors.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is one of the largest pharmaceutical services companies in the United States. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation, bedside medication safety systems, and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $48 billion in operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 14,000 people. AmerisourceBergen is ranked #22 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. Forward-looking statements may include statements addressing AmerisourceBergen's future financial and operating results.

The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer relationships; customer insolvencies; changes in customer mix; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; regulatory changes; changes in U.S. government policies (including changes in government policies pertaining to drug reimbursement); changes in market interest rates; and other economic, business, competitive, regulatory and/or operational factors affecting the business of AmerisourceBergen generally.

More detailed information about these and other risk factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2004.

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward looking statements whether as a result of new information, future events or otherwise.


    CONTACT: AmerisourceBergen Corporation, Valley Forge
             Michael N. Kilpatric, 610-727-7118
             mkilpatric@amerisourcebergen.com

    SOURCE: AmerisourceBergen Corporation

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More